tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Nuvectis Pharma price target lowered to $10 from $15 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Nuvectis Pharma (NVCT) to $10 from $15 and keeps a Buy rating on the shares. The firm removed NXP800 from its projections. The deprioritization of NXP800 allows Nuvectis to better deploy capital in assets with a greater chance of success in the clinic, the analyst tells investors in a research note.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1